Terazosin hydrochloride

Terazosin Hydrochloride is the hydrochloride salt form of terazosin, a quinazoline derivative with adrenergic antagonistic property. Terazosin hydrochloride selectively inhibits alpha-1 adrenergic receptors, resulting in vasodilation leading to decreased peripheral vascular resistance and a reduced venous return to the heart as well as decreased urethral resistance, which potentially improving urine flow and symptoms related to benign prostatic hyperplasia. Additionally, terazosin decreases low-density lipoproteins (LDL) and triglycerides while increasing the concentration of high-density lipoproteins (HDL). It is grouped under the following drug class(es): Alpha-1 Blockers. Its therapeutic use is listed as urological agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Hytrin, Zayasel, Vasocard and Terazosin hydrochloride anhydrous. Its PubChem CID is 44383.